DOCSLIB.ORG

The NIH and Rdna Guidelines Explained

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The NIH and Rdna Guidelines Explained Clemson University IBC Page 1 of 8 The NIH rDNA Guidelines Explained The next few pages were written to extract the essence of the NIH guideline requirements and put them into readable form. Since many details are omitted, the actual guidelines should be consulted when in doubt (http://www4.od.nih.gov/oba/rac/guidelines.html). Plant, whole animals, and human experiments are given special treatment in the guidelines (and in this explanation). PREREQUISITES To make sense of the following, the reader should know the basic ideas behind Biosafety Levels 1 through 4. A summary table giving the characteristics of the four laboratory Biosafety Levels is on page 6. Animal Biosafety levels are summarized on page 7. WHAT IS RECOMBINANT DNA (rDNA)? It is either a) DNA constructed in vitro from separate DNA segments that can replicate and/or express a biologically active polynucleotide or polypeptide in vivo, or b) synthetic DNA that has the potential of generating a hazardous product in vivo. WHAT ARE THE RAC AND THE OBA? The NIH OBA (Office of Biotechnology Activities) is an administrative arm responsible for carrying out the orders of the NIH Director with regard to recombinant DNA, genetic testing, and xenotransplantation. An advisory committee is involved in establishing policies for each of these fields. For recombinant DNA the committee is called the Recombinant DNA Advisory Committee or the “RAC”. REGISTRATION The NIH requires all labs working with recombinant DNA to register with their local Institutional Biosafety Committee (IBC). The guidelines distinguish among the five kinds of registrations. The type depends on the potential hazard of the work. More hazardous means more approvals are needed. The five types are: Work that cannot begin until there is NIH and IBC approval (NIH Guidelines Sections III-A and III-B), this is the most dangerous level and it is [TABOO] (page 2) Work that cannot begin until there is IBC and RAC review (Sections III-C). [WAIT and WAIT] (page 2) This tends to be sensitive and potentially dangerous. Human Gene Transfer studies are in this category (page5). Work that cannot begin until there is IBC approval (III-D), there is usually a short [WAIT] (page 2). Work can begin when the IBC is notified (Section III-E) [NO WAITING] (page 4) Work that is Exempt form NIH Guidelines (Section III-F). No approval is needed but the work should be registered with the IBC [NO WAITING, EXEMPT] (page 4) Clemson University IBC Page 2 of 8 “TABOO” (NIH approval and IBC Approval Required) (from NIH Guidelines Sections III-A and III-B) Making drug resistant constructs of microorganisms if they compromise the drug’s therapeutic potential Making constructs that synthesize vertebrate toxins with an LD50 of 100ng/Kg or less. Making constructs in E. coli that synthesize vertebrate toxins that are “lethal” between 100ng/Kg and 100µg/Kg “WAIT AND WAIT” (NIH Review and IBC Approval Required) (from Section IIIC) Studies in which genes are transferred into humans must be submitted to the NIH OBA for review. If the OBA finds the study to be “novel” it will place the study on the next RAC meeting agenda. IBC approval must wait for the RAC’s review. If, on the other hand, OBA does not deem the study to be “novel”, IBC can act immediately. “WAIT” (IBC Approval Needed Before Starting) These studies are examined by the IBC with an eye to recommending safe procedures and containment. To reach a conclusion it is often useful to classify the risk associated with a proposed study according to the risk associated with the organism(s) to be used. A convenient classification tool is the concept of “risk group”. Risk Groups The NIH classifies biological agents into four Risk Groups according to their human pathogenecity (see NIH Guidelines, Section II-A-1) · Risk Group 1 – not associated with disease in healthy adults · Risk Group 2 – associated with disease that is rarely serious and for which therapeutic or preventive options are often available · Risk Group 3 - associated with serious or lethal disease for which therapeutic or preventive options may be available · Risk Group 4 – associated with serious or lethal disease for which therapeutic or preventive options not usually available Appendix B in the NIH Guidelines lists a number of biologic agents according to their Risk Group. Clemson University IBC Page 3 of 8 In general, the Risk Group determines the Biosafety Level needed: for instance a Risk Group 3 agent is usually studied in a BL3 or BL3-N (animal) or BL3-P (plants) lab. Those agents not listed in Risk Group (RGs) 2, 3 and 4 are not automatically or implicitly I RG1: a risk assessment must be conducted based on the known and potential properties of the agents and their relationship to agents that are listed. The table on the next page summarizes the NIH recommendations for Biosafety Level according to risk group. “NO WAITING” Just Notify IBC Before Work Starts Notification is necessary because all recombinant DNA studies must be registered with Clemson University. These studies involve “Low Hazard” recombinant DNA (Section III-E) · Non-pathogenic prokaryotes or non-pathogenic lower eukaryotes (use BL1) · Recombinant DNA with less than 2/3 of a eukaryotic viral genome (and no helper) used exclusively in tissue culture (BL1 recommended) · Some host Plants carrying recombinant DNA. BL1-P level containment is recommended when the host is: a non-noxious weed, a plant or microorganism thought not to damage the ecosystem, · Some other host Plants carrying recombinant DNA. BL3-P or BL1-P+ level containment is recommended when: the host is a noxious weed, the introduced DNA is the complete genome of an infectious agent known to normally exist in the U.S. the host is a plant or microorganism that may damage ecosystems, the host is a plant with recombinant DNA from foreign microorganisms that is thought to be safe for the ecosystem. No Waiting - Exempt Exempt Recombinant DNA (Section III-F and Appendix C) “Exempt” form NIH guidelines means that work with these constructs need not be approved by the IBC. However, Clemson University requires that all recombinant work, exempt or non- exempt, be registered. Thus, it is Clemson University policy to insist that investigators using any recombinant DNA register with the IBC. The exempt work can be performed at BL1. Clemson University IBC Page 4 of 8 Gene transfer into Human subjects (RAC review process1 is required before IBC can approve this kind of study). (Section III-C-1) Recombinant organisms cultured in volumes greater than 10 liters (Section III-D-6). Pathogen Hosts (Section III-D-1): Check Appendix B to determine their Risk Group - then: Risk Group 2 host. BL2, BL2-N Risk Group 3 host. BL3, BL3-N Risk Group 4 host. BL4, BL4-N Pathogen DNA Source into Non-Pathogen Host (Section III-D-2): Check Appendix B to determine their Risk Group - then: Risk Group 2 or 3 source. BL2 Risk Group 4 source. .BL2, IF the pathogen genome is defective Risk Group 4 source. .BL4, Otherwise Animal Virus DNA source into Tissue Culture (Section III-D-3): Check Appendix B to determine their Risk Group- then: Risk Group 2 virus source. .BL2 Risk Group 3 virus source. .BL3 Risk Group 4 virus source. .BL4 Transgenic Animal2 Host (Section III-D-4): Anything but > 2/3 eukaryotic virus genome. BL1-N (but IBC can boost this level based on the pathogenicity of the source organism) Viral vectors that don't transmit. BL1-N Everything else is a special case. .IBC decides Modified microorganisms into Animals: (Section III-D-4): Any viable rDNA modified organism ≥BL2, BL2-N rDNA into Animals Any rDNA that (except pieces >⅔ eukaryotic viral genome) . .BL1, BL1-N Everything else. IBC decides Whole Plants: (Section III-D-5) Exotic3 pathogen hosts that can dam- age the ecosystem. BL3-P or BL2-P+ Plants with transmissible DNA from exotic pathogens that can damage the ecosystem. .BL3-P or BL2-P+ Transmissible exotic pathogen hosts BL4-P Toxin DNA into plants. BL3-P Insect Pathogen DNA that can dam- age the ecosystem. BL3-P or BL2-P+ Genes coding for vertebrate Toxins (Appendix F) LD50 < 100 ng/kg . .Requires NIH & IBC approval 100 ng/kg < LD50 < 100 μg/kg . Requires IBC approval & NIH notifi- cation. (except in E. coli-see below) 100 ng/kg < LD50 < 1 μg/kg . .BL2 if in E. coli 1 μg/kg < LD50 < 100 μg/kg. BL1 if in E. coli ____________________________________________________ 1RAC can either take no action and transmit the protocol to the FDA or call for a full public review at one of its quarterly meetings. 2The purchase or transfer of transgenic rodents is exempt from the NIH guidelines. 3"Exotic" plant pathogens are defined as those not known to occur naturally in the US. _________________________________________________________________________________________________ Clemson University IBC Page 5 of 8 Some Exempt Classes are: · DNA vaccines encoding epitopes from microbiological sources are generally exempt from the NIH Guidelines, even in human studies. This unusual exemption is found in Appendix VI-A. · Recombinant DNA outside of living or viral organisms, · Recombinant DNA that cannot replicate or express in vivo, · DNA from a single nonchromosomal or viral source, ·The DNA source organism and the host organism are the same organism (but not released into the environment) · The DNA source organism and the host organism normally exchange DNA (organisms that normally exchange are listed in Appendix A) · DNA that does “not present a significant risk to health or the environment...” ·The recombinant DNA is used exclusively in tissue culture and has <1/2 eukaryotic viral genome.
Load more

Recommended publications
  • The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
    The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The Executive summary The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow.
    [Show full text]
  • Genome As a Tool of Genetic Engineering: Application in Plant and Plant Derived Medicine
    International Journal of Biotech Trends and Technology (IJBTT) – Volume 8 Issue 1- Jan - March 2018 Genome as a Tool of Genetic Engineering: Application in Plant and Plant Derived Medicine A.B.M. Sharif Hossain1,2 Musamma M. Uddin2 1Department of Biology, Faculty of Science, Hail University, Hail, KSA 2Biotechnology Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia introduce point mutations. Genetically modified Abstract organism (GMO) is considered as an organism that The study was conducted from different is generated through genetic engineering. The first modern research data to review the innovative GMOs were bacteria in 1973, GM mice were generated in 1974 [4]. Insulin-producing bacteria latest technology in the genomics and its were commercialized in 1982 and genetically application in Agriculture, biomedicinae and modified food has been sold since 1994. Glofish, the plant derived medicine. Application of genome first GMO designed as a pet, was first sold in the in genetic engineering and molecular United States December in 2003 [4]. Genetic biotechnology have been exhibited well. engineering biotechnology has been applied in Genetically Modified Organism (GMO), numerous fields including agriculture, industrial Agrobacterium mediated recombination (T- biotechnology, and medicine. Enzymes used in DNA) and genetic engineering using molecular laundry detergent and medicines such as insulin and Biotechnology in plant, medicine and human growth hormone are now manufactured in biomedicine have been highlighted from GM cells, experimental GM cell lines and GM animals such as mice or zebra fish are being used for technology based different research data. research purposes, and genetically modified Moreover, molecular biotechnology in crops have been commercialized [4].
    [Show full text]
  • Review of the Current State of Genetic Testing - a Living Resource
    Review of the Current State of Genetic Testing - A Living Resource Prepared by Liza Gershony, DVM, PhD and Anita Oberbauer, PhD of the University of California, Davis Editorial input by Leigh Anne Clark, PhD of Clemson University July, 2020 Contents Introduction .................................................................................................................................................. 1 I. The Basics ......................................................................................................................................... 2 II. Modes of Inheritance ....................................................................................................................... 7 a. Mendelian Inheritance and Punnett Squares ................................................................................. 7 b. Non-Mendelian Inheritance ........................................................................................................... 10 III. Genetic Selection and Populations ................................................................................................ 13 IV. Dog Breeds as Populations ............................................................................................................. 15 V. Canine Genetic Tests ...................................................................................................................... 16 a. Direct and Indirect Tests ................................................................................................................ 17 b. Single
    [Show full text]
  • DNA Testing and the Next Generation of Environmental Forensics
    DNA Testing and the Next Generation of Environmental Forensics Andrew M. Deines, Ph.D.; William L. Goodfellow, Jr., BCES; Karen J. Murray, Ph.D. Historically, assessing species presence has relied on a time consuming and labor intensive process. Advances in genetic testing techniques provide a faster, cheaper, and more accurate taxonomic assessment, which can be used to answer a range of environmental and ecological questions. The rapid advancements and substantial reduction in cost for DNA sequencing in the field of human genomics has created an opportunity to use the same technologies and specific modifications for broad use in environmental and ecological studies – from baseline studies to risk and impact assessments. In the last two decades the development of genetic sequencing technology and the expansion of the field of genomics (analysis of an organism’s entire genetic code) has unlocked information hidden within cells, transforming the world of medical diagnostics and providing avenues to additional scientific discovery. In the field of human genetics, researchers are nearing the goal of providing a human genome for $1000 using “next-generation” sequencing— what scientists call new high-throughput and high resolution genetic tools. These same DNA sequencing methods are being applied to many aspects of environmental and ecological study. DNA sequencing technology reported in the academic literature has addressed important evolutionary and ecological questions, leading to the development of new fields of study such as environmental genetics and conservation genomics. The development of new techniques almost monthly creates a wealth of opportunities for environmental assessments. Rapid DNA sequencing allows for the exploration of the genetic make-up of individual animals, populations, and assemblages of species in astonishing detail.
    [Show full text]
  • Guide to Biotechnology 2008
    guide to biotechnology 2008 research & development health bioethics innovate industrial & environmental food & agriculture biodefense Biotechnology Industry Organization 1201 Maryland Avenue, SW imagine Suite 900 Washington, DC 20024 intellectual property 202.962.9200 (phone) 202.488.6301 (fax) bio.org inform bio.org The Guide to Biotechnology is compiled by the Biotechnology Industry Organization (BIO) Editors Roxanna Guilford-Blake Debbie Strickland Contributors BIO Staff table of Contents Biotechnology: A Collection of Technologies 1 Regenerative Medicine ................................................. 36 What Is Biotechnology? .................................................. 1 Vaccines ....................................................................... 37 Cells and Biological Molecules ........................................ 1 Plant-Made Pharmaceuticals ........................................ 37 Therapeutic Development Overview .............................. 38 Biotechnology Industry Facts 2 Market Capitalization, 1994–2006 .................................. 3 Agricultural Production Applications 41 U.S. Biotech Industry Statistics: 1995–2006 ................... 3 Crop Biotechnology ...................................................... 41 U.S. Public Companies by Region, 2006 ........................ 4 Forest Biotechnology .................................................... 44 Total Financing, 1998–2007 (in billions of U.S. dollars) .... 4 Animal Biotechnology ................................................... 45 Biotech
    [Show full text]
  • The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
    International Journal of Molecular Sciences Review The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases Lyes Toualbi 1,2, Maria Toms 1,2 and Mariya Moosajee 1,2,3,4,* 1 UCL Institute of Ophthalmology, London EC1V 9EL, UK; [email protected] (L.T.); [email protected] (M.T.) 2 The Francis Crick Institute, London NW1 1AT, UK 3 Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK 4 Great Ormond Street Hospital for Children NHS Found Trust, London WC1N 3JH, UK * Correspondence: [email protected]; Tel.: +44-207-608-6971 Abstract: Inherited retinal diseases (IRDs) are a heterogeneous group of disorders causing progres- sive loss of vision, affecting approximately one in 1000 people worldwide. Gene augmentation therapy, which typically involves using adeno-associated viral vectors for delivery of healthy gene copies to affected tissues, has shown great promise as a strategy for the treatment of IRDs. How- ever, the use of viruses is associated with several limitations, including harmful immune responses, genome integration, and limited gene carrying capacity. Here, we review the advances in non-viral gene augmentation strategies, such as the use of plasmids with minimal bacterial backbones and scaffold/matrix attachment region (S/MAR) sequences, that have the capability to overcome these weaknesses by accommodating genes of any size and maintaining episomal transgene expression with a lower risk of eliciting an immune response. Low retinal transfection rates remain a limita- tion, but various strategies, including coupling the DNA with different types of chemical vehicles (nanoparticles) and the use of electrical methods such as iontophoresis and electrotransfection to aid Citation: Toualbi, L.; Toms, M.; Moosajee, M.
    [Show full text]
  • View the Lower Court’S Findings Concerning Infringement De Novo
    Nos. 04-1532, 05-1120/-1121 In the United States Court of Appeals for the Federal Circuit MONSANTO COMPANY, Plaintiff/Appellee, v. MITCHELL SCRUGGS, EDDIE SCRUGGS, SCRUGGS FARM & SUPPLIES, LLC; SCRUGGS FARM JOINT VENTURE; HES FARMS, INC.; MES FARMS, INC.; and MHS FARMS, INC., Defendants/Appellants. Appeals from the United States District Court for the Northern District of Mississippi, Case No. 00-cv-161, Judge W. Allen Pepper, Jr. BRIEF OF AMICUS CURIAE CENTER FOR FOOD SAFETY Joseph Mendelson III* Andrew Kimbrell Center for Food Safety 660 Pennsylvania Ave., SE Suite 302 Washington, DC 20003 (202) 547-9359 Attorneys for Amicus Curiae *Counsel of Record May 9, 2005 TABLE OF CONTENTS CERTIFICATE OF INTEREST .......................................... TABLE OF CONTENTS ............................................... i TABLE OF AUTHORITIES ........................................... ii STATEMENT OF INTEREST OF AMICUS CURIAE ..................... 1 ARGUMENT ........................................................ 3 I. Introduction .................................................. 3 II. Farmers Do Not Infringe the Monsanto Patents. ......................................................... 9 A. Limited Scope of Monsanto’s Patent Claims. ................................................... 10 B. American Farmers Do Not Plant Chimeric Genes, Promoters or Plant Cells. ................................................... 14 III. Extension of Monsanto’s Narrow Patent Claims to Seeds and Plants Will Have Significant Impacts on Farmers and Consumers.
    [Show full text]
  • Molecular Genetic Testing Introduction, Evolution, and Future
    Scholars in HeAlth Research Program Molecular Genetic Testing Introduction, Evolution, and Future Rami Mahfouz MD, MPH Why Study Genetics? Statistics Spontaneous Miscarriages A chromosome abnormality is present in at least 50% of all first-trimester pregnancy loss Newborn Infants 2% of all neonates have a single gene disorder or a chromosome abnormality Childhood Genetic disorders account for 50% of all blindness, deafness, and mental retardation Adult Life At least 10% of common cancers (such as breast and colon) have a genetic etiology Genetics and Medicine • Cancer • Diabetes • Cardiovascular Disease (Hypertension, Myocardial infarction, etc..) • Psychiatric disorders (Schizophrenia, ..) Terms to familiarize with GENE - The basic hereditary unit. It’s a DNA sequence required for production of a functional product. ALLELE - One of the alternate versions of a gene present in a population. LOCUS - Literally a “place” on a chromosome or DNA molecule. Usually refers to the location of the gene. GENETICS – The study of genes. GENOMICS – The study of genes interaction. GENOTYPE - An individual’s genetic constitution. PHENOTYPE - Observable expression of genotype. Human Genome Project Estimated number of genes ~25,000 We humans are 99.9% identical at the DNA sequence level Only 1 to 1.5% of the genome encodes proteins DNA contains information equal to some 600,000 printed pages of 500 words each!!! (a library of about 1,000 books) DNA Structure Source: cnx.org/content/m12382/latest Features of DNA structure Storing and coding Semi-conservative
    [Show full text]
  • Report of Investigation MT140008-BR
    UNITED STATES DEPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE INVESTIGATIVE AND ENFORCEMENT SERVICES REPORT OF INVESTIGATION Case Number: MT140008-BR Monsanto Company Registered Agent: Subject(s): 800 North Lindbergh Boulevard Corporation Service Company (Contact Information) Saint Louis, Missouri 63167 2711 Centerville Road, Suite 400 Phone: (314) 694-1000 Wilmington, DE 19808 Fax: (314) 694-2306 Phone: (302) 636-5400 Web: www.monsanto.com Fax: (302) 636-5454 E-mail: [email protected] Montana State University, Southern Agricultural Research Center 748 Railroad Highway Huntley, Montana 59037 Phone: (406) 348-3400 Fax: (406) 348-3410 Web: www.sarc.montana.edu Investigator: (Contact Information) USDA, APHIS, IES 2150 Centre Avenue, Bldg. B-3W10 Fort Collins, Colorado 80526 Date of Report: October 7, 2015 Substantiated allegation(s) No violation(s) Insufficient evidence Fact finding Contains Confidential Business Information FOR OFFICIAL USE ONLY This document and its contents are not to be distributed outside your agency, or duplicated, without prior consent from USDA APHIS Investigative and Enforcement Services. Case Number: MT140008-BR Date: October 7, 2015 Reviewer: , Area Director Page 2 of 61 Case Number: MT140008-BR Date: October 7, 2015 SYNOPSIS On 07/07/14, Montana State University (MSU), Southern Agricultural Research Center (SARC) notified for the Monsanto Company (Monsanto) that wheat volunteers1 growing in a field at SARC appeared to be resistant to Roundup2. In addition, informed Monsanto representatives that Enzyme- Linked Immunosorbent Assay3 (ELISA) tests indicated the volunteers were positive for the CP4 EPSPS4 protein. In response, and two other Monsanto representatives visited MSU, SARC on 07/09/14 to observe the wheat volunteers and collect samples.
    [Show full text]
  • Monsanto Company and KWS SAAT AG Supplemental Request for Partial Deregulation of Sugar Beet Genetically Engineered to Be Tolerant to the Herbicide Glyphosate
    Monsanto Company and KWS SAAT AG Supplemental Request for Partial Deregulation of Sugar Beet Genetically Engineered to be Tolerant to the Herbicide Glyphosate Final Environmental Assessment February 2011 Agency Contact: Cynthia Eck Document Control Officer Biotechnology Regulatory Services USDA APHIS Riverdale, MD 20737 The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, sex, religion, age, disability, political beliefs, sexual orientation, or marital or family status. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.) should contact USDA’S TARGET Center at (202) 720–2600 (voice and TDD). To file a complaint of discrimination, write USDA, Director, Office of Civil Rights, Room 326–W, Whitten Building, 1400 Independence Avenue, SW, Washington, DC 20250–9410 or call (202) 720–5964 (voice and TDD). USDA is an equal opportunity provider and employer. Mention of companies or commercial products in this report does not imply recommendation or endorsement by the U.S. Department of Agriculture over others not mentioned. USDA neither guarantees nor warrants the standard of any product mentioned. Product names are mentioned solely to report factually on available data and to provide specific information. This publication reports research involving pesticides. All uses of pesticides must be registered by appropriate State and/or Federal agencies before they can be recommended. Page 1 of 369 Summary APHIS has received a supplemental request from Monsanto/KWS to amend the petition for non- regulated status submitted in 2003 (Petition 03-323-01) pursuant to the regulatory scheme of 7 CFR Part 340.
    [Show full text]
  • Genetic Testing Services
    Genetic Testing Services Charles River’s genotyping core processes thousands of samples per week for leading biopharmaceutical companies, world-renowned academic institutions, and a host of government agencies. Our full-service molecular-based genetic characterization laboratory is equipped to run multiple types of allele-specific assays including PCR, qPCR, SNP, and TaqMan® assays. While the overall process is highly automated for fast turnaround, our flexible, responsive laboratory can readily respond to scale up or expedited testing requests as driven by customer demand. Effective colony management depends on genotyping results, not just data. Quality reporting is of the utmost importance; our trained staff not only reviews each submission to ensure the accuracy of results, but also that they concur with available information on the breed scheme, knowledge of the assay, and sample quality. Each order automatically checks reported genotypes against breed schemes to help identify incorrect breeders early before they impact a colony too greatly. Combining multi-platform technology and expertise in laboratory animal genetics, our laboratory is unmatched in its ability to provide scientific and customer support with comprehensive information about their colonies for utmost ease of management. The ever increasing complexity of genetically engineered models often requires additional support with understanding what results mean, and how to interpret them to best manage breeding colonies. Our team can readily assist clients with questions about
    [Show full text]
  • Genetic Cloning and Testing
    Genetic Cloning and Testing BACKGROUND Genetic Cloning or years, humans successfully have used myriad genetic techniques—from GLOSSARY Fselective breeding to genetic manipulation—to create plants and animals Chromosome with desirable characteristics. Corn has been genetically engineered to improve Units in the nucleus of a cell, resistance to fungus and viral infections, rot, and drought, and calves have been composed of DNA, that contain genes; normal human somatic cells genetically altered to accelerate the growth process, to cite two examples. contain 46 chromosomes (23 pair). Clone Genetic cloning is a comparatively new process that uses the DNA contained in Duplicate. cells to “clone,” or duplicate, strands of DNA, cells, or organisms to achieve DNA Deoxyribonucleic acid; the material exact copies of the original. These genetic clones are analogous to identical inside the nucleus of a cell that human twins—two genetically identical individuals whose development can be carries genetic information. traced to the division of a single embryo. For some time, scientists have known Embryo The prefetal product of conception that multiple animals could be created in the same way that human twins are from implantation through the 12th created: by dividing a single embryo into multiple embryos shortly after fertiliza- week of development. An embryo conceived through sexual tion. This creates offspring that are genetically identical to each other and have reproduction receives half its genetic received their genetic information from each sexual parent (half from the male, information from each sexual parent—that is, half comes from half from the female). the sperm and half from the egg.
    [Show full text]